REVERSED
Tech Center 1700 Chemical & Materials Engineering
1777 Ex Parte Burbank et al 11813472 - (D) McMANUS 103 Potomac Law Group, PLLC MENON, KRISHNAN S
Tech Center 2100 Computer Architecture and Software
2167 Ex Parte Kannan et al 13755664 - (D) ENGLE 102/103 Hewlett Packard Enterprise PHAM, MICHAEL
2194 Ex Parte Lee et al 12813635 - (D) STRAUSS 103 Hewlett Packard Enterprise MUDRICK, TIMOTHY A
Tech Center 2400 Networking, Multiplexing, Cable, and Security
2433 Ex Parte CANNING et al 14092252 - (D) McNEILL 103 AMY PATTILLO IBM CORP (AP) ANDERSON, MICHAEL D
2461 Ex Parte Nosley 12308719 - (D) ANDERSON 103 Kunzler Law Group - Lenovo BEDNASH, JOSEPH A
Tech Center 2600 Communications
2646 Ex Parte Ahluwalia et al 13339022 - (D) BUSCH 103 LEYDIG VOIT & MAYER, LTD SHEDRICK, CHARLES TERRELL
2691 Ex Parte SAKAI 12466408 - (D) McCARTNEY 102 WOLF GREENFIELD & SACKS, P.C. YANG, KWANG-SU
Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3753 Ex Parte Deng 12842821 - (D) STEPINA 103 MIDDLETON & REUTLINGER CAHILL, JESSICA MARIE
AFFIRMED-IN-PART
Tech Center 1600 Biotechnology and Organic Chemistry
1651 Ex Parte Bayer et al 13865321 - (D) POLLOCK 102/103 102/103 CARELLA, BYRNE, CECCHI, OLSTEIN, BRODY & AGNELLO ARIANI, KADE
1675 Ex Parte CANNON et al 12913174 - (D) GRIMES 112(2)/112(4)/102 101 MCTAVISH PATENT FIRM HA, JULIE
We agree with the Examiner that claim 1 is not patent-eligible subject matter. Claim 1 is directed to a peptide that is made up of a fragment of the naturally occurring matriptase protein. Thus, the Supreme Court opinion in Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S.Ct. 2107 (2013), is controlling. In Myriad, the Court considered claims directed to isolated DNA encoding the BRCA1 polypeptide and fragments of at least 15 nucleotides of that DNA. Id. at 2113.
The Court held that “Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.” Id. at 2117. “Myriad found the location of the BRCA1 and BRCA2 genes, but that discovery, by itself, does not render the BRCA genes ‘new . . . composition[s] of matter,’ § 101, that are patent eligible.” Id. “Nor are Myriad’s claims saved by the fact that isolating DNA from the human genome severs chemical bonds and thereby creates a nonnaturally occurring molecule.” Id. at 2118.
Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. _, 133 S. Ct. 2107, 106 USPQ2d 1972 (2013) 2103 , 2106
Tech Center 2600 Communications
2696 Ex Parte Jiang 13726523 - (D) DEJMEK 103 103 PEIGEN JIANG JANSEN II, MICHAEL J
Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2872 Ex Parte Broadway et al 12923838 - (D) MOORE 102 102/103 NIXON & VANDERHYE, PC MADONNA, JEFFREY E
AFFIRMED
Tech Center 1600 Biotechnology and Organic Chemistry
1615 Ex Parte Eloy et al 14006745 - (D) FLAX 103 BUCHANAN, INGERSOLL & ROONEY PC TCHERKASSKAYA, OLGA V
1629 Ex Parte BENATAR et al 13442213 - (D) MILLS 103 THE FIRM OF HUESCHEN AND SAGE FINN, MEGHAN R
1651 Ex Parte Walker 13399960 - (D) FLAX 102 103 Foley & Lardner LLP Kythera Biopharmaceuticals, Inc. FAN, LYNN Y
Tech Center 1700 Chemical & Materials Engineering
1726 Ex Parte Schimmele et al 13318523 - (D) GUEST 103 IP GROUP OF DLA PIPER LLP (US) CONLEY, OI K
2169 Ex Parte Lipson et al 12975192 - (D) MOORE 103 KILPATRICK TOWNSEND & STOCKTON LLP KIM, PAUL
Tech Center 2600 Communications
2625 Ex Parte Taylor 12350857 - (D) MOORE 103 MORRISS OBRYANT COMPAGNI, P.C. OKEBATO, SAHLU
2694 Ex Parte Rogoza 12193314 - (D) ENGELS 103 DALY, CROWLEY, MOFFORD & DURKEE, LLP RAYTHEON COMPANY HUGHES, EBONIN
Tech Center 2800 Semiconductors, Electrical and Optical Systems and Components
2883 Ex Parte Bradea et al 13206157 - (D) KENNEDY 102 CORNING INCORPORATED ROJAS, OMAR R
Tech Center 3700 Mechanical Engineering, Manufacturing, and Products & Design
3777 Ex Parte Henning et al 13486188 - (D) BAHR 103 SCHIFF HARDIN, LLP BRUTUS, JOEL F
